PLMO, COTE, OPGX, IOVE, October 22 Stock to Watch from OTCPicks.com

Our Stocks to Watch tomorrow include Pulmo BioTech Inc. (OTCBB: PLMO), Coates International Ltd. (OTCBB: COTE), Optigenex Inc. (OTC: OPGX) and Accredited Business Consolidators Corp. (OTC: IOVE).

PULMO BIOTECH INCORPORATED (OTCBB: PLMO)

"Up 166.67% on Wednesday"

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

PLMO News:

October 21 - Pulmo BioTech Inc. Announces Further Details of its Previously Announced Letter of Intent Intended to Bring its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ to the European Market

Pulmo BioTech Inc. (OTCBB: PLMO) (Frankfort Borse: PBO) has announced has announced further details of its non-binding letter of intent with Biotechnology Consulting Poland Sp. z.o.o. to license its Pulmonary Vascular Diagnostic Product Candidate PulmoBind™ development work, clinical trials and ultimately, commercialization in the European market.

"Biotechnology Consulting Poland will license the technology of PulmoBind™ from Pulmo BioTech pursuant to a License Agreement expected to be entered into before the end of 2009. This will enable Biotechnology Consulting Poland to carry out Phase I trials in Europe starting in early 2010. Once these safety and efficacy trials are completed and if approval has been granted by the European Regulatory Authority it is intended that Biotechnology Consulting Poland will immediately commence Phase II/III trials for PulmoBind™ against the conditions of pulmonary hypertension and pulmonary embolism. Pursuant to the License Agreement, Biotechnology Consulting Poland will ultimately be responsible for the commercialization of PulmoBind™ across the whole of the European Union and the European Economic Area. It is contemplated that the License Agreement will have an initial term of six years, with an extension clause, and during this period Pulmo BioTech will provide all of the technical information and resources necessary to enable Biotechnology Consulting Poland to successfully complete all of its European trials work. By utilizing the technical and commercial skills of Biotechnology Consulting Poland, Pulmo BioTech will have European trials of PulmoBind™ in tandem with the work in North America, which will permit Pulmo BioTech to complete trials and begin commercialization in parallel across these two continents." - Garry McCann, CEO Pulmo BioTech Inc.

ABOUT PULMOSCIENCE INC.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind™.

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind™ Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

ABOUT PULMOBIND™

PulmoBind™ uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind™ has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind™ will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind™ could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

ABOUT BIOTECHNOLOGY CONSULTING POLAND SP. Z.O.O.

BioTechnology Consulting Poland Sp. z.o.o. is a Polish based company which has been set up to enable the rapid approval of products developed outside the Euro Zone in the European market.

Pursuant to the License Agreement contemplated by the LOI, BioTechnology Consulting Poland will license IP from Pulmo BioTech to enable it to rapidly carry out Phase Trials and ultimately commercialize PulmoBind™ across the whole of the European Union and European Economic Area.

BioTechnology Consulting Poland counts amongst its key staff, professionals in the areas of medical project management, new business start-up and growth, and medical Phase Trials. BioTechnology Consulting Poland has links with key Polish medical facilities, CROs and Pharmaceutical companies.

COATES INTERNATIONAL LIMITED (OTCBB: COTE)

"Up 64.10% on Wednesday"

Coates has been developing over a period of more than 15 years a patented spherical rotary valve CSRV Internal Combustion Engine invented by George J. Coates and his son Gregory. The CSRV system is adaptable to combustion engines of many types. This technology is currently adapted to a number of practical applications, including industrial generators powered by engines incorporating the CSRV technology and designed to operate on flare-off gas from oil wells, landfill gas and raw natural gas. The Company is actively engaged in preparing for the commencement of manufacturing of products utilizing this technology.

COTE News:

October 21 - Coates International Ltd. Signs Bond Issue Deal for $300,000,000 USD

Coates International, Ltd. (OTCBB: COTE) (the "Company"). After many months of intense negotiation the company on October 20, signed a Joint Venture (Entity) to process a bond offering, that the net proceeds will be $300,000,000 USD for the company. This funding is specifically for the start up of two manufacturing and production facilities, one in Miami, Oklahoma and the other in New Jersey not far from the existing Coates world headquarters facility in Wall Township, New Jersey. This transaction was initiated by George J. Coates, President, CEO and Barry Kaye, CFO.

George J. Coates, President and CEO, stated this is a very exciting and important prospect for our company. These funds will facilitate large scale manufacturing of our Coates CSRV Industrial Electric Power Natural Gas Generators and the 18 Wheeler Tractor Trailer Diesel CSRV Engines, of which the company has large orders for both of these products.

The Company's large scale manufacturing plans will require the creation of thousands of new quality permanent jobs and substantial capital expenditures that we believe will help boost the U.S. economy. Our world-wide patented Coates Spherical Rotary Valve (CSRV) System technology lowers the consumption of fossil fuels and will reduce the U.S. dependency on imported foreign oil, while lowering harmful exhaust emissions that are released into our atmosphere.

We have previously entered into an agreement with Oklahoma which would enable us to qualify for a package of business and tax incentives by hiring plant workers and making capital expenditures in the state that could amount to as much as approximately $750 million. Barry Kaye, Chief Financial Officer, stated: "The business and tax incentives in Oklahoma, coupled with the opportunity to utilize our substantial net operation loss carryforwards to offset income taxes will give us an additional advantage by improving our profitably in the early stages of our manufacturing phase of operations."

OPTIGENEX INCORPORATED (OTC: OPGX)

"Up 60.00% on Wednesday"

Optigenex inc. is a formulator, distributor and provider of proprietary next generation skin care, supplements and bulk ingredient featuring AC-11® (Formerly known as C-MED-100®) a patented compound as it core product. AC- 11® is the bioactive, water soluble form of the medicinal herb Uncaria tomentosa.

OPGX News:

October 21 - Optigenex Inc. Announces Supply And License Agreement With Suracell Inc. To Utilize The AC-11® Trademark And Technology For Oral Supplements In The United States, Canada And South Korea

Optigenex Inc. (OTC: OPGX) announced the signing of a Supply and Trademark License Agreement with Suracell Inc. to provide its patented ingredient AC-11® for use in a focused nutritional and age management dietary supplement program. The agreement coupled with Suracell's marketing plans will provide another platform to introduce Optigenex's technology under the registered trademark AC-11® to health conscious consumers in the United States, Canada and South Korea.

Beginning in January 2010, Suracell will be marketing a specific dietary supplement regimen. Participants will complete lifestyle questionnaires and will be asked to provide specimens for testing of key bio markers that will form the basis for a focused nutritional supplement program utilizing the diverse line of Suracell formulated products with AC-11®.

All-natural, herbal-extracted and patented AC-11® is marketed by over 100 manufacturers and marketing companies in Japan, Europe, the Middle East, the United States and Canada in a variety of anti-aging cosmetic, dietary supplement and advanced DNA care products.

Daniel Zwiren, president and CEO of Optigenex Inc. said, "We are excited to add Suracell to our family of customers. We believe Suracell's scientifically validated formulas are an ideal fit for the unique properties of AC-11®, including natural DNA repair, immune enhancement and inhibition of pro-inflammatory agents. The licensing relationship we are entering into today will allow both companies to expand significantly their respective businesses and market penetration.

A Suracell spokesperson added, "The addition of AC -11® to the proprietary customized Suracell formulations gives us a product line unparalleled in its potential benefits to its customers. The evolving science surrounding AC 11® promises a very exciting future for our product offerings.

ABOUT SURACELL INC.

Suracell Inc. provides personal genetic health programs formulated to measure, assess treat and monitor the body's individual genetic needs. The testing and analysis programs are designed to pinpoint deficiencies and damage in an individual's DNA and provide personalized recommended protocols consisting of specially formulated nutraceuticals and positive lifestyle choices.

ACCREDITED BUSINESS CONSOLIDATORS CORP. (OTC: IOVE)

"Up 23.26% on Wednesday"

Accredited Business Consolidators Corp., formerly known as the Italian Oven, is a diversified holding corporation. Visit www.accreditedbiz.com (under construction) for information on its affiliated companies. The total number of common shares outstanding is 436,399,500. 328,018,200 shares are in the public float and on hand with CEDE & Co., 70,546,600 shares are restricted in certificate form, and 37,834,700 shares are unrestricted but in certificate form. There will be no increase in shares until at least April 2010.

IOVE News:

October 20 - Accredited Business Consolidators Corp. to Divest Richwood Eco Ventures Inc. and to Issue Dividend

Accredited Business Consolidators Corp., trading as Italian Oven, Inc. (OTC: IOVE), issued a resolution to divest the Company's Richwood Eco Ventures Inc. subsidiary.

IOVE will begin the paperwork to obtain a CUSIP for the subsidiary and will subsequently issue a one for one dividend to present shareholders of IOVE. That is, for every share of IOVE, one share of Richwood Eco Ventures would be issued to the IOVE shareholder. The ex date will be set in the next three to six weeks. Richwood Eco Ventures maintains a share structure of 999,999,999 authorized shares.

After the issuance of the dividend and the close of the fiscal year, the Company will take the appropriate action necessary to have the financial statements of Richwood Eco Ventures Inc. audited and to register the securities in question with the Securities and Exchange Commission. Once registered, the Company will attempt to secure a market maker for the registered securities so that a trading symbol may be obtained from FINRA.

This divesture is mutually exclusive from the planned issuance of Accredited Consolidators Europe PLC shares to IOVE common shareholders at the rate of 1 ACE PLC share for every 250 IOVE shares. (There will only be 5,000,000 shares of ACE PLC.)

About OTCPicks.com

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks has not been compensated by any of the companies covered in this release.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.